Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase I	Treatment	Active	18 and over	Pharmaceutical / Industry	CA184-078 NCT00796991

Trial Description

Summary

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

Eligibility Criteria

Inclusion Criteria:

• Histologic diagnosis of advanced malignant melanoma

• ECOG performances status 0-1

• Measurable/evaluable disease as per mWHO criteria

Exclusion Criteria:

• Evidence of active brain metastases

• Prior treatment with anti-CTLA-4 or anti-CD137 antibody

• Total Bilirubin > 1.5 x ULN and AST or ALT > 2.5 x ULN

• Prior Autoimmune disease

• Use of immunosuppressing therapies

Trial Contact Information

Trial Lead Organizations/Sponsors

Bristol-Myers Squibb Company - New York

Bristol-Myers Squibb

Study Director

For participation information at a USA site use a phone number below. For site information outside the USA please email:
		Email: Clinical.Trials@bms.com

First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.

U.S.A.
California
	Los Angeles
	Angeles Clinic and Research Institute - Los Angeles
		Omid Hamid, Site 002
Florida
	Tampa
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
		Jeffrey Weber, Site 001
New York
	New York
	Mem Sloan-Ket Can Ctr
		Jedd D. Wolchok, Site 004
North Carolina
	Charlotte
	Carolinas Med Ctr
		Asim Amin, Site 005

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00796991
Information obtained from ClinicalTrials.gov on May 07, 2009